PHOENIXVILLE, Pa. — PleoPharma Inc., a privately held company focused on finding treatments for cannabis-related health issues, closed a $36M Series B financing round.
PleoPharma will use the proceeds to advance its lead asset, PP-01, an investigational product for treating cannabis use disorder.
SuperVision Partners LLC served as the lead placement agent for the offering along with Castle Hill Capital Partners Inc.
Related Articles:
Advertisement
